Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($0.12), $0.21 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $127.78 million versus the consensus estimate of $107.36 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.